NSE · RPGLIFE
RPG Life Sciences Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹196 Cr with net profit ₹31 Cr — a 15.62% net margin, versus 15.71% the period before.
Shareholding
As of 2026-06-30
- Promoter72.95%
- Public17.42%
- FII0.95%
- DII8.67%
23,886 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.78× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #34 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,80,827 Cr | 38.69 | 5.75 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,18,535 Cr | 213.58 | 3.44 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,242 Cr | 20.48 | 4.1 | 18.59% | 18.86% |
| Lupin Limited | ₹1,10,769 Cr | 19.48 | 4.93 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,06,264 Cr | 52.75 | 6.52 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,305 Cr | 88.06 | 18.17 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,411 Cr | 431.36 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹91,447 Cr | 99.27 | 2.41 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,551 Cr | 294.23 | 5.03 | 16.66% | 15.65% |
| Biocon Ltd. | ₹68,962 Cr | 538.54 | 2.03 | 1.14% | 2.3% |
| RPG Life Sciences Ltd.(this company) | ₹4,605 Cr | 39.4 | 7.61 | 19.03% | 16.29% |
AI analysis
AI-generated · google/gemini-2.5-flashRPG Life Sciences Ltd. is listed with a market capitalization of Rs 4990 Cr. The company reported revenue of Rs 733.1 Cr and a net profit margin of 16.28%. Its earnings per share (EPS) for the last fiscal year stood at Rs 66.31.
Positives
- +The debt-to-equity ratio is low at 0.02, indicating minimal reliance on debt.
- +The promoter shareholding is substantial at 72.95% as of March 31, 2026.
- +The company's Return on Capital Employed (ROCE) is 24.66%, indicating efficient use of capital.
- +The dividend yield is 80%, providing a high return to shareholders.
Negatives
- −The trailing twelve-month P/E ratio is high at 166.88, which might suggest a premium valuation.
- −No quarterly revenue growth figure was provided in the data.
- −No quarterly profit growth figure was provided in the data.
- −No annual revenue growth figure was provided in the data.
- −No EPS figures were provided for the quarterly results from March 2025 to March 2026.
Financial Performance
For the fiscal year ending March 2026, RPG Life Sciences Ltd. reported a total revenue of Rs 733.1 Cr. The corresponding net profit for the year was Rs 115.17 Cr, resulting in an EPS of Rs 69.64. In the most recent quarter ending March 2026, the company posted revenue of Rs 176.89 Cr and a net profit of Rs 29.9 Cr.
Profitability & Returns
The company achieved a profit margin of 16.28%. Its Return on Equity (ROE) was 19.03%, while the Return on Capital Employed (ROCE) stood at 24.66%. The basic EPS for the last fiscal year was Rs 66.31.
Balance Sheet
RPG Life Sciences Ltd. has a debt-to-equity ratio of 0.02, indicating a low reliance on debt financing. The book value per share is Rs 366.01.
Ownership & Pledges
As of March 31, 2026, promoters held 72.95% of the company's shares. Public shareholding was 18.73%, while institutions held 8.32% (comprising DIIs at 7.45% and FIIs at 0.87%). There were no promoter pledges reported.
Data as of — price: 2026-07-30 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.